obesity drug news today glp-1 october 27 2025 GLP‑1 real‑world data for obesity: A new standard for metabolic care New Daily GLP-1 Weight Loss

Although this large, rigorous trial can provide support for a potential new indication for semaglutide for secondary prevention of CVD, whether and how quickly payers may reimburse for such an indication is uncertain

Several GLP-1 medications are available, including Ozempic, Wegovy, Saxenda, Trulicity, Mounjaro and Zepbound

If youre considering GLP-1 treatment, discuss your individual risk factors and medical history with your doctor

Short-Term Effectiveness of Low Dose Liraglutide in Combination With Metformin Versus High Dose Liraglutide Alone in Treatment of Obese PCOS: Randomized Trial

Furthermore, increased research activities for developing innovative drugs and formulations, rising demand, ease of administration of injectables with immediate onset of action, availability of single-dose formulations in the market and utilization of social media platforms as well as celebrity endorsements for promoting GLP-1 receptor agonists are the factors boosting the market growth of this segment

Critics of GLP-1 therapies often portray those who use these medications as opting for an easy way out to achieve thinness, perpetuating longstanding biases like those historically associated with bariatric surgery (Heitmann, 2025)